Skip to content

Harm-reduction information only — not medical advice. In crisis or experiencing adverse effects, contact a healthcare professional or your local emergency services immediately.

AnabolicPlotter logo AnabolicPlotter
Search (no-JS fallback)
Anabolic Steroids/Hormones Preclinical (animal) data

Boldenone Undecylenate (Equipoise)

EQ · Equipoise · Boldenone

14 days
Half-life
200–600 mg
Typical dose
2×/week
Frequency
10–14 weeks
Cycle length

Equipoise; long half-life, slow steady gains. Notorious for long detection times.

Key takeaways

  • Veterinary long-acting testosterone analog (Equipoise); no current approved human use.
  • ~14-day half-life, peak around day 6; steady state takes weeks and clearance is slow.
  • Aromatizes weakly and isn't hepatotoxic; hematocrit and long detection windows are the practical concerns.
  • Human data is thin; most PK understanding is extrapolated from veterinary and analog studies.

Overview

What it is

Boldenone undecylenate (Equipoise, EQ) is a long-acting injectable androgen developed for veterinary use; the human version (Parenabol) was withdrawn decades ago. It's a testosterone analog with a 1,4 double bond that reduces androgenic and estrogenic activity, and it drives erythropoiesis strongly, which feeds its reputation for endurance and slow, lean gains.

Pharmacokinetics

The undecylenate ester gives a ~14-day half-life with a peak around 6 days post-injection and ~63% bioavailability. Levels build slowly, so steady state takes many weeks; community protocols inject once or twice weekly.

Harm reduction

Not hepatotoxic, and aromatization is weak relative to testosterone, but hematocrit can climb and detection windows run long. HPTA suppression is real, and the long ester means slow clearance after the last shot.

Reported dosing protocols

Protocols reported in research literature and clinic/community use — informational context, not a dosing recommendation.

Use case Dose Route Frequency Duration
Performance (community) 200–600 mg weekly IM 1–2× weekly 10–14 weeks

Pharmacokinetic summary

Model tier
Advanced (t½ + Cmax + Tmax + F)
Half-life
14 days
Cmax
600 ng/dL
Tmax
6.0 days
Bioavailability
63%
Typical dose
200–600 mg

Harm reduction

Aromatizes
Yes
DHT derivative
No
Injection frequency
2×/week

Frequently asked questions

Is Equipoise approved for humans?

No. Boldenone undecylenate is a veterinary product approved for horses. A human formulation (Parenabol) existed briefly in the 1970s and was withdrawn. Anything available today is veterinary or underground-lab product.

Why do EQ cycles run so long?

The undecylenate ester's ~14-day half-life means blood levels take 4–6 weeks to approach steady state, so short cycles end before the compound reaches full effect. Community protocols typically run 10–14 weeks to match that kinetics.

Does boldenone raise red blood cell count?

Yes; erythropoiesis stimulation is pronounced, which is part of why it interested clinicians originally. Hematocrit monitoring matters, especially stacked with other androgens. Weak aromatization means fewer estrogenic effects, not fewer cardiovascular ones.

References

Related articles

Related compounds

Protocols featuring Boldenone Undecylenate (Equipoise)

Comments

Loading comments…